Citius Pharmaceuticals Inc [NASDAQ: CTXR] stock went on an upward path that rose over 10.64% on Tuesday, amounting to a one-week price increase of more than 6.17%.
Over the last 12 months, CTXR stock dropped by -38.14%. The one-year Citius Pharmaceuticals Inc stock forecast points to a potential upside of 81.75. The average equity rating for CTXR stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $131.89 million, with 180.67 million shares outstanding and 166.70 million shares in the current float. Compared to the average trading volume of 974.83K shares, CTXR stock reached a trading volume of 21609685 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Citius Pharmaceuticals Inc [CTXR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTXR shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTXR stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Citius Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 30, 2021.
The Average True Range (ATR) for Citius Pharmaceuticals Inc is set at 0.07 The Price to Book ratio for the last quarter was 1.46, with the Price to Cash per share for the same quarter was set at 0.07.
CTXR Stock Performance Analysis:
Citius Pharmaceuticals Inc [CTXR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.17. With this latest performance, CTXR shares dropped by -0.57% in over the last four-week period, additionally sinking by -5.55% over the last 6 months – not to mention a drop of -38.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTXR stock in for the last two-week period is set at 51.96, with the RSI for the last a single of trading hit 57.13, and the three-weeks RSI is set at 50.04 for Citius Pharmaceuticals Inc [CTXR]. The present Moving Average for the last 50 days of trading for this stock 0.7684, while it was recorded at 0.6661 for the last single week of trading, and 0.7675 for the last 200 days.
Insight into Citius Pharmaceuticals Inc Fundamentals:
Citius Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.17 and a Current Ratio set at 5.17.
Citius Pharmaceuticals Inc [CTXR] Institutonal Ownership Details
The top three institutional holders of CTXR stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in CTXR stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in CTXR stock with ownership which is approximately 5.8386%.
